CN113046414A - Kit for human fecal pathogenic microorganism genome library construction and sequencing method - Google Patents
Kit for human fecal pathogenic microorganism genome library construction and sequencing method Download PDFInfo
- Publication number
- CN113046414A CN113046414A CN202110275849.XA CN202110275849A CN113046414A CN 113046414 A CN113046414 A CN 113046414A CN 202110275849 A CN202110275849 A CN 202110275849A CN 113046414 A CN113046414 A CN 113046414A
- Authority
- CN
- China
- Prior art keywords
- tube
- nucleic acid
- supernatant
- library
- standing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010276 construction Methods 0.000 title claims abstract description 21
- 244000000010 microbial pathogen Species 0.000 title claims abstract description 16
- 238000012163 sequencing technique Methods 0.000 title abstract description 12
- 230000002550 fecal effect Effects 0.000 title abstract description 7
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 41
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 41
- 238000000605 extraction Methods 0.000 claims abstract description 21
- 239000003623 enhancer Substances 0.000 claims abstract description 20
- 238000005406 washing Methods 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004472 Lysine Substances 0.000 claims abstract description 9
- 239000012148 binding buffer Substances 0.000 claims abstract description 9
- 239000003112 inhibitor Substances 0.000 claims abstract description 9
- 239000011324 bead Substances 0.000 claims description 51
- 239000006228 supernatant Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 36
- 238000002156 mixing Methods 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 239000002904 solvent Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 20
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 19
- 230000003321 amplification Effects 0.000 claims description 17
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 17
- 238000000227 grinding Methods 0.000 claims description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000007664 blowing Methods 0.000 claims description 9
- 230000009089 cytolysis Effects 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- 230000002255 enzymatic effect Effects 0.000 claims description 8
- 238000006911 enzymatic reaction Methods 0.000 claims description 8
- 229920004890 Triton X-100 Polymers 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 239000012154 double-distilled water Substances 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 238000010009 beating Methods 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 4
- 239000013504 Triton X-100 Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 238000011033 desalting Methods 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 238000013467 fragmentation Methods 0.000 claims description 4
- 238000006062 fragmentation reaction Methods 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- KDRNOBUWMVLVFH-UHFFFAOYSA-N 2-methyl-n-(2,2,6,6-tetramethylpiperidin-4-yl)prop-2-enamide Chemical compound CC(=C)C(=O)NC1CC(C)(C)NC(C)(C)C1 KDRNOBUWMVLVFH-UHFFFAOYSA-N 0.000 claims description 3
- 101000740112 Homo sapiens Membrane-associated transporter protein Proteins 0.000 claims description 3
- 102100037258 Membrane-associated transporter protein Human genes 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000012224 working solution Substances 0.000 claims description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 2
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 2
- 239000008118 PEG 6000 Substances 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 claims description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 2
- 230000010355 oscillation Effects 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000012408 PCR amplification Methods 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 5
- 230000002860 competitive effect Effects 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 7
- 238000007689 inspection Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000007400 DNA extraction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000010296 bead milling Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kit for establishing a human fecal pathogenic microorganism genome library and a sequencing method. The invention relates to a nucleic acid extraction kit for establishing a pathogenic microorganism genome library in human excrement, which comprises the following components: nucleic acid release agent lysine A, Enhancer lysine Enhancer, inhibitor IRT, Binding Buffer, washing solution 1 and washing solution 2. The invention optimizes the nucleic acid extraction link, and the extracted DNA has high purity and high yield, so as to ensure the normal operation of downstream tests even under the condition of limited sample size. Meanwhile, the PCR amplification conditions are optimized, the initial quantity of DNA library construction is reduced, the library construction success rate is improved, the PCR amplification bias is reduced, the library construction period is shortened, and the pain points that the existing library construction method has high requirement on the initial quantity of the template, the bias is easy to occur, the library construction period is long and the like are overcome.
Description
Technical Field
The invention belongs to the field of DNA extraction and library construction, and particularly relates to a kit and a sequencing method for constructing a human fecal pathogenic microorganism genome library.
Background
The traditional clinical model for diagnosing infectious diseases of patients is to make differential diagnosis by doctors and then perform a series of tests to try to find out the cause of the disease. Routine detection of pathogens in clinical samples ranges from identification of microorganisms growing in culture (e.g., by biochemical phenotypic detection or matrix-assisted laser desorption/ionization (MALDI) time-of-flight mass spectrometry), detection of organism-specific biomarkers (e.g., antigen by latex agglutination assays or enzyme-linked immunosorbent assays (ELISA) antibody assays or nucleic acid assays using PCR on individual reagents).
Although molecular diagnostic assays provide a reasonably cost effective and rapid method for diagnosing the most common infections (< 2h turn-around time in general). However, almost all conventional microbiological tests currently in use can only detect one or a limited number of pathogens at a time, or require successful culture of microorganisms from clinical specimens.
Fortunately, a new etiologic diagnostic technology, mNGS (metagenomic second-generation sequencing), a method of sequencing all nucleic acids in a clinical sample and then comparing with the genome sequence of each species to find possible pathogens, would be expected to solve this problem. The mNGS can not only greatly shorten the sample turnover time, but also provide accurate and favorable diagnosis and treatment basis for clinic in time.
Currently, as one of the most important molecular biological analysis methods, mNGS not only provides important data for basic biological studies such as genetic information disclosure and gene expression regulation, but also plays an important role in application studies such as gene diagnosis and gene therapy. Since 2005, high throughput sequencing technologies were successively born and developed, as labeled by 454 technology by Roche, Solexa technology by Illumina, and SOLiD technology by ABI. Sequencing is achieved by the mNGS, typically by the following three steps: 1) obtaining nucleic acid molecules containing a region to be determined by a PCR amplification technology; 2) connecting different linker molecules to two ends of a nucleic acid molecule containing a target region to be determined respectively to obtain a determination library; 3) the universal primer amplifies the ligation product to the amount required for sequencing.
However, the amount of nucleic acid extracted from some precious samples is very limited, and the nucleic acid amount of the samples cannot meet the requirement of the on-machine process after the traditional host and other steps are usually carried out, so that the PCR cycle number is increased and the amplification bias is aggravated through PCR amplification, and thus, a serious problem occurs in the identification of bacteria with high GC content, and the abundance ratio of the strains is seriously unbalanced. Meanwhile, the problem that the period of partial library building kit is too long and the like exists.
In view of this, there is still a need in the prior art for a new rapid method suitable for micro-clinical library construction to simplify the experimental steps and improve the library construction efficiency.
Disclosure of Invention
The invention provides a kit and a sequencing method for a pathogenic microorganism gene library in human excrement, which optimize the nucleic acid extraction link, have high purity and high yield of extracted DNA and ensure that downstream tests can be normally carried out even under the condition of limited sample quantity. Meanwhile, the PCR amplification conditions are optimized, the initial quantity of DNA library construction is reduced, the library construction success rate is improved, the PCR amplification bias is reduced, the library construction period is shortened, and the pain points that the existing library construction method has high requirement on the initial quantity of the template, the bias is easy to occur, the library construction period is long and the like are overcome.
The first object of the present invention is to provide a nucleic acid extraction kit for the genomic library of pathogenic microorganisms in human feces, which comprises: a nucleic acid releasing agent Lysis A, a reinforcing agent Lysis Enhancer, a de-inhibitor IRT, a Binding solution Binding Buffer, a washing solution 1 and a washing solution 2;
the nucleic acid releasing agent lysine A comprises 20 mM-40 mM EDTA, 40 mM-80 mM Tris-HCl, 2% -5% PVP-40 (mass fraction), a solvent DEPC water and a pH value of 9-10;
the Enhancer lysine Enhancer comprises 12-15% of SDS (mass fraction), 4-8% of PVP-40 (mass fraction) and DEPC water as a solvent.
Preferably, the nucleic acid releasing agent LysisA comprises 20mM EDTA, 50mM Tri-HCl, 2% PVP-40 (mass fraction) and DEPC water as a solvent, the Enhancer Lysis Enhancer comprises 15% SDS (mass fraction) and 5% PVP-40 (mass fraction) and DEPC water as a solvent.
Preferably, the de-inhibitor IRT comprises: 120mM NH4Al(SO4)2.12H2O, DEPC water is used as a solvent, and the pH value is 3.0-4.0;
preferably, the Binding solution Binding Buffer comprises: 3M guanidinium isothiocyanate, 16.7% isopropanol (V/V), 2% Triton X100(V/V), 10mM EDTA, 5mM Tris-HCl in DEPC water at pH 6.0-7.0;
the washing solution 1 comprises: 20% ethanol (V/V), 20% isopropanol (V/V), 70mM sodium chloride, 20mM Tris-HCl, DEPC water as solvent, and pH 6.0-7.0;
the washing liquid 2 comprises: 70% ethanol (V/V), 20mM Tris-HCl, DEPC water as solvent, pH 6.0-7.0.
The second purpose of the invention is to provide a kit for fragmenting treatment and end-modifying part of a pathogenic microorganism genome library in human excrement, which comprises AC buffers and AC Enzymes;
the AC Buffer comprises: 500mM Tris-HCl, 200mM KCl, 100mM MgCl2, 1mM DTT, 10mM ATP, 10mM dATP, 2mM dTTP, 2mM dGTP, 2mM dCTP, 0.1% Triton X-100(v/v), and the solvent is DEPC water;
the AC Enzymes comprise: 1.5U/ul T4 Polynucleotide Kinase (Enzymatics, Y9040L), 1U/ul T4 DNA Polymerase (Enzymatics, P7080L), 0.5U/ul Klenow Fragment (Enzymatics, P7060L), 1U/ul Taq-B DNA Polymerase (Enzymatics, P7250L), 4mM Tris-HCl, 5mM KCl, 0.8mM DTT, 0.2mM EDTA, 22% (mass fraction) Glycerol, 0.5% Triton X-100(v/v), and DEPC water as a solvent.
The third purpose of the invention is to provide a kit for connecting and enriching joints of a pathogenic microorganism gene building library in human excrement, which comprises Ligation XP and AD Buffer;
the Ligation XP comprises: 14% Glycerol (v/v), 20% PEG-6000 (mass fraction), 25% 1,2-Propanediol (v/v), 40mM Tris-HCl, 10mM MgCl2, 10mM MATP, 10mM DTT, 80U/ul Rapid 4 DNAIGAse (EnzyValley), and DEPC water as a solvent;
the AD Buffer comprises: 10mM Tris-HCl, 0.5mM EDTA, 50mM NaCl, and DEPC water as solvent.
The fourth purpose of the invention is to provide a nucleic acid extraction method of a pathogenic microorganism genome library in human excrement, which comprises the following steps:
nucleic acid release: transferring the excrement sample to a bead grinding tube for grinding beads, adding a nucleic acid releasing agent LysisA and an Enhancer Lysis Enhancer into the sample, performing vortex scattering on the sample, incubating, and putting the grinding tube into a bead grinding instrument for bead grinding;
inhibitor removal: transferring all the supernatant into a centrifuge tube, adding inhibitor-removed IRT into the supernatant, uniformly mixing by vortex, and centrifuging;
column adsorption, namely transferring the supernatant into a centrifuge tube, adding Binding solution Binding Buffer into the supernatant, reversing and uniformly mixing to obtain mixed solution, putting a purification column into a collection tube, transferring the mixed solution into a column, centrifuging to discard effluent, and putting the column back into the collection tube;
desalting: adding washing solution 1 into the column, centrifuging, pouring off the filtrate, putting the column back into the collecting pipe, adding washing solution 2 into the column, centrifuging, repeating the operation of washing solution 2 for several times, pouring off the filtrate, putting the column back into the collecting pipe, and centrifuging;
nucleic acid elution: the column was placed in a centrifuge tube, sterilized water was added to the center of the membrane of the column, and the column was left at room temperature and then centrifuged to obtain nucleic acid.
The fifth object of the present invention is to provide a method for banking genomes of pathogenic microorganisms in human excrement, which comprises the following steps:
dna fragmentation:
preparing a breaking system in 50ul breaking pipes, and selecting corresponding breaking time according to different breaking systems:
B. end repair (A-Tailed Conversion):
preparing a terminal repair reaction system in a 0.2mL PCR tube:
Fragment ds_DNA | 25μL |
AC Buffer | 3μL |
AC Enzymes | 2μL |
Total Volume | 30μL |
blowing and beating for at least 10 times or carrying out vortex oscillation and uniform mixing, and carrying out short-time centrifugation to collect liquid on the pipe/hole wall;
the reaction system was placed on a PCR instrument with the hot lid set at 80 ℃ and the following procedure was run:
·20℃ 30min;
·65℃ 30min;
·4℃ Forever
C. connecting joints:
5min before the ligation reaction, the Adapter working solution was prepared according to the following table and placed on ice for use:
DNA input | Dilution |
50ng-500ng | No dilution |
5ng-50ng | 10-fold |
the following reagents were added directly to the end-repair reaction system:
A-Tailing cDNA | 30μL |
Ligation XP | 20μL |
Adapter(for illumina) | 5μL |
Total Volume | 55μL |
placing the reaction system on a PCR instrument, setting the temperature of a hot cover as Off, and incubating for 20min at 20 ℃;
D. fragment selection and purification
Insert Size | ~150bp | 150-250bp | 250-350bp | 350-450bp | 450-550bp | >550bp |
1st Beads Vol.(μL) | 50 | 40 | 30 | 25 | 20 | 15 |
2nd Beads Vol.(μL) | 25 | 20 | 15 | 10 | 10 | 10 |
Taking the Fapon DNA clean Beads out, standing to room temperature, and uniformly mixing in a vortex manner for later use;
to a 1.5mL tube or octal tube was added 30. mu.L ddH2Adding O +30 mu LFapon DNAclear Beads into 55 mu L of the reaction product in the previous step, uniformly mixing by vortex, collecting the liquid on the tube wall instantly, and standing for 5min at room temperature;
placing a 1.5mL tube or an eight-connected tube on a magnetic frame until the solution in the tube is clarified;
carefully sucking the supernatant into a new 1.5mL EP tube or an eight-linked tube, adding 15 μ L Fapon DNA clean Beads, mixing well, and standing at room temperature for 5 min;
placing the EP tube or the eight-connected tube on a magnetic frame, and removing supernatant after the solution in the tube is clarified;
adding 200 mu L of freshly prepared 80% ethanol into an EP tube or an eight-connection tube, rotating a 1.5mL tube for one circle, standing the eight-connection tube for 30s, and then removing a supernatant;
repeating the steps, and removing the supernatant as much as possible;
placing a 1.5mL tube or an eight-connection tube on a magnetic frame, standing at room temperature for 10min until the magnetic beads are dried or opening the tube and placing the tube on a 45 ℃ metal bath until the surfaces of the magnetic beads are free of water;
removing the centrifugal tube from the magnetic frame, adding 22 mu L of ddH2O for resuspension of magnetic beads, uniformly mixing by vortex or blowing, collecting the liquid on the tube wall instantly, and standing at room temperature for 2 min;
placing the EP tube or the eight-connected tube on a magnetic frame, transferring 20 mu L of supernatant into a new PCR tube after the solution in the tube is clarified, and carrying out the next amplification;
C. library amplification:
preparing a library amplification reaction system on an ice box:
setting up a library amplification reaction program:
the cycle numbers are referenced as follows:
Total DNA input | Recommended PCR cycles | Total DNA input | Recommended PCR cycles |
1ug | 5 | 50ng | 10-11 |
500ng | 6-8 | 10ng | 12-13 |
100ng | 8-9 | 5ng | 13-15 |
D. and (3) purifying an amplification product:
vortex Fapon DNA clean Beads, resuspend them;
transferring the PCR product to a new 1.5mL tube or an eight-connected tube, adding 0.8X 40 mu L Fapon DNA clean Beads, mixing uniformly by vortex, collecting the tube wall liquid instantly, and standing at room temperature for 5 min;
placing 1.5mL tube or eight-connected tube on a magnetic frame, standing for 2min, and standing until the solution in the tube is clear;
carefully sucking and discarding supernatant liquid, adding 200 μ L of newly prepared 80% ethanol into the tube, rotating the tube on a magnetic frame, and discarding supernatant after the solution is clarified;
repeating the steps, and removing the supernatant as much as possible;
placing a 1.5mL tube or an eight-connection tube on a magnetic frame, standing at room temperature for 10min until the magnetic beads are dried or opening the tube and placing the tube on a 45 ℃ metal bath until the surfaces of the magnetic beads are free of water;
adding 28 μ L ddH2O into the EP tube or the eight-link tube, blowing, beating, mixing, standing for 2min, and placing the EP tube on a magnetic frame until the liquid becomes clear;
and sucking 25 mu L of supernatant into a new 1.5mL EP tube, adhering a library label on the tube wall, using Qsep400 to check the quality to be qualified, and storing the product in a special library storage position at the temperature of-20 ℃.
The invention optimizes the nucleic acid extraction link, and the extracted DNA has high purity and high yield, so as to ensure the normal operation of downstream tests even under the condition of limited sample size. Meanwhile, the PCR amplification conditions are optimized, the initial quantity of DNA library construction is reduced, the library construction success rate is improved, the PCR amplification bias is reduced, the library construction period is shortened, and the pain points that the existing library construction method has high requirement on the initial quantity of the template, the bias is easy to occur, the library construction period is long and the like are overcome.
Description of the drawings:
FIGS. 1 and 2 are pre-machine Qsep400 quality checks of the library;
FIG. 3 is the results of sequencing data generating analysis.
The specific implementation mode is as follows:
the following examples are further illustrative of the present invention and are not intended to be limiting thereof. It should be understood that these examples are only for the purpose of the present invention and are not intended to limit the scope of the present invention. Unless defined or indicated otherwise, the scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
Example 1:
firstly, preparing a reagent of a nucleic acid extraction part of the kit:
nucleic acid releasing agent Lysis a: 20mM EDTA, 50mM Tri-HCl, 2% PVP-40 (mass fraction), and DEPC water as a solvent.
Enhancer lysine Enhancer: 15% SDS (mass fraction), 5% PVP-40 (mass fraction), and DEPC water as solvent.
De-inhibitor IRT: 120mM NH4Al(SO4)2.12H2O, DEPC water is used as a solvent, and the pH value is 3.0-4.0;
binding solution Binding Buffer: 3M guanidinium isothiocyanate, 16.7% isopropanol (V/V), 2% Triton X100(V/V), 10mM EDTA, 5mM Tris-HCl in DEPC water at pH 7.0;
washing solution 1: 20% ethanol (V/V), 20% isopropanol (V/V), 70mM sodium chloride, 20mM Tris-HCl, DEPC water as solvent, pH 6.4;
washing solution 2: 70% ethanol (V/V), 20mM Tris-HCl, DEPC water as solvent, and pH 6.4;
the preparation method comprises the following steps: adding the above components according to their content, mixing, adjusting pH, and filtering with 0.22um filter membrane (raw technology, F513134-0001) for sterilization;
secondly, the extraction method of the nucleic acid extraction part of the kit comprises the following steps:
nucleic acid release: transfer 2-3 soybean-sized fecal samples to a 2ml bead mill tube containing milling beads. Immediately adding 800ul of nucleic acid releasing agent Lysis A and 100ul of enhancing agent Lysis Enhancer into the sample, vortexing at the maximum for 1min to fully disperse the sample, and incubating at 65 ℃ for 20 min. The grinding tube was put into a bead mill for bead milling at a strength of 30m/s for 15s, and repeated 3 times.
Inhibitor removal: transferring all the supernatant into a 1.5ml centrifuge tube, adding 100ul of inhibitor-removed IRT into the supernatant, mixing uniformly by vortex, standing at 4 ℃ for 5min, and centrifuging for 1min at 12,000x g;
column passing adsorption: transferring the whole supernatant (about 1ml) to a 2ml centrifuge tube, adding 1ml Binding Buffer to the supernatant, mixing by inversion, and placing the purification column (crude, B615025-1000) in a 2ml collection tube. Transfer 700. mu.l of the mixture to the column. Centrifuging for 30-60 s at 12,000x g. Pouring out the effluent, and putting the column back into the collecting pipe;
desalting: the filtrate was decanted and the column was returned to the collection tube. Add 500uL of Wash 1 to the column, centrifuge for 1min at 8,000Xg, discard the filtrate and load the column back into the collection tube. Add 500uL of Wash 2 to the column. Centrifuge at 8,000Xg for 1min, repeat washing 2 times, discard filtrate, pack column back into collection tube. Centrifuging at 8,000Xg for 3 min;
nucleic acid elution: the column was placed in a 1.5ml centrifuge tube. Adding 30-50 μ l of sterilized water preheated to 70 deg.C to the center of the membrane of the column, and standing at room temperature for 3 min. Centrifuge for 1min at 12,000x g.
Thirdly, a competitive product kit: magen fecal DNA extraction kit (cat # D3141) and assist in san-saint fecal DNA extraction kit (cat # 18820ES50)
The extraction steps are as follows:
nucleic acid release: transfer 2-3 soybean-size stool samples to a 2ml bead mill tube containing milling beads. Immediately adding 600 mu LBufferaTL/PVP-10 into a sample, putting a grinding tube into a bead grinding instrument for bead grinding, wherein the strength is 30m/s, the time is 15s, repeating for 3 times, and incubating for 10min at 65 ℃; 13,000x g for 10min, transfer 500. mu.l of the supernatant to a 2ml centrifuge tube, and add 20. mu.l of protease K and 500. mu.l of Buffer AL to the supernatant. Mix by inversion and digest at 70 ℃ for 10 min. Cooled to room temperature, 500. mu.l of absolute ethanol was added to the mixture, and vortexed and mixed for 15 seconds.
Column passing adsorption: HiPure DNA Mini Column II was loaded into a 2ml collection tube. Transfer 700. mu.l of the mixture to the column. Centrifuging for 30-60 s at 12,000x g. And pouring out the effluent, putting the column back into the collecting pipe, and centrifuging the residual mixed solution according to the steps until the transfer is finished.
Desalting: 500 μ L of Buffer GW1 diluted with ethanol was added to the column. Standing for 2min, and centrifuging for 30-60 s at 12,000x g. Pouring out the effluent, and putting the column back into the collecting pipe; 650 μ L of Buffer GW2 diluted with ethanol was added to the column. Standing for 2min, and centrifuging for 30-60 s at 12,000x g. Pouring out the effluent, and putting the column back into the collecting pipe; centrifuge for 2min at 12,000x g to dry the column.
Nucleic acid elution: the column was placed in a 1.5ml centrifuge tube. Adding 30-50 μ l of sterilized water preheated to 70 deg.C to the center of the membrane of the column, and standing at room temperature for 3 min. Centrifuge for 1min at 12,000x g.
Detection of the concentration and OD value of the DNA
The DNA extracted by the kit and the competitive product kit is subjected to concentration and OD detection by using Nandrop 300
Sample numbering | A | B | C | D | E | F |
Concentration (ng/ul) | 451.708 | 474.141 | 234.592 | 254.354 | 207.06 | 251.115 |
A260/A280 | 2.09 | 2.18 | 1.72 | 1.68 | 1.858 | 1.944 |
A260/A230 | 1.06 | 1.21 | 1.59 | 1.72 | 1.741 | 1.219 |
Note: a and B are the results of the extraction portion of the kit of the invention, C and D are the results of the competitive product extraction kit 1 (magenta, D3141), E and F are the competitive product extraction kit 2 (assist in san, 18820ES50)
From the results, the nucleic acid concentration of the same volume of the specimen obtained by the extraction method of the present invention using the kit of the present invention is higher than that of the competitive reagent kit, and the purity is also superior to that of the competitive reagent kit.
Fourthly, preparing a kit library building part as follows:
AC Buffer: 500mM Tris-HCl, 200mM KCl, 100mM MgCl2, 1mM DTT, 10mM ATP, 10mM dATP, 2mM dTTP, 2mM dGTP, 2mM dCTP, 0.1% Triton X-100(v/v), and the solvent is DEPC water;
AC Enzymes: 1.5U/ul T4 Polynucleotide Kinase (Enzymatics, Y9040L), 1U/ul T4 DNA Polymerase (Enzymatics, P7080L), 0.5U/ul Klenow Fragment (Enzymatics, P7060L), 1U/ul Taq-B DNA Polymerase (Enzymatics, P7250L), 4mM Tris-HCl, 5mM KCl, 0.8mM DTT, 0.2mM EDTA, 22% Glycerol (mass fraction), 0.5% Triton X-100(v/v), and DEPC water as solvent;
ligation XP: 14% Glycerol (v/v), 20% (mass fraction) PEG-6000, 25% 1,2-Propanediol (v/v), 40mM Tris-HCl, 10mM MgCl210mM ATP, 10mM DTT, 80U/ul Rapid T4 DNA Ligase (EnzyValley) and DEPC water as a solvent;
AD Buffer: 10mM Tris-HCl, 0.5mM EDTA, 50mM NaCl, and DEPC water as solvent;
the preparation method comprises the following steps: adding the above components according to their content, mixing, and filtering with 0.22um filter membrane (raw technology, F513134-0001) for sterilization;
the kit nucleic acid library building part library building method comprises the following steps:
isometric mixing of front-end extracted nucleic acid products A and B to obtain a sample 1, isometric mixing of front-end extracted products C and D to obtain a sample 2, isometric mixing of front-end extracted nucleic acid products E and F to obtain a sample 3, and entering three samples into a downstream experiment;
dna fragmentation (DNAFragment):
preparing a breaking system in 50ul breaking pipes, and selecting corresponding breaking time according to different breaking systems:
B. end repair (A-Tailed Conversion):
preparing a terminal repair reaction system in a 0.2mL PCR tube:
Fragment ds_DNA | 25μL |
AC Buffer | 3μL |
AC Enzymes | 2μL |
Total Volume | 30μL |
blowing (at least 10 times) or vortex, shaking, mixing, and centrifuging for a short time to collect liquid on the tube/hole wall;
the reaction system was placed on a PCR instrument with the hot lid set at 80 ℃ and the following procedure was run:
·20℃ 30min;
·65℃ 30min;
·4℃ Forever
C. connector Ligation (Adapter Ligation):
5min before preparation of the ligation reaction, Adapter working solution (Adapter, illumina platform sequence, AD Buffer for dilution) was prepared according to the following table and placed on ice for use:
DNA input | Dilution |
50ng-500ng | No dilution |
5ng-50ng | 10-fold |
the following reagents were added directly to the end-repair reaction system:
A-Tailing cDNA | 30μL |
Ligation XP | 20μL |
Adapter(for illumina) | 5μL |
Total Volume | 55μL |
placing the reaction system on a PCR instrument, setting the temperature of a hot cover as Off, and incubating for 20min at 20 ℃;
D. fragment selection and purification (Post-Ligation Clean-up)
Insert Size | ~150bp | 150-250bp | 250-350bp | 350-450bp | 450-550bp | >550bp |
1st Beads Vol.(μL) | 50 | 40 | 30 | 25 | 20 | 15 |
2nd Beads Vol.(μL) | 25 | 20 | 15 | 10 | 10 | 10 |
Note: the following purification procedure is exemplified by 300bp
Taking the Fapon DNA clean Beads out, standing to room temperature, and uniformly mixing in a vortex manner for later use;
to a 1.5mL tube or octal tube was added 30. mu.L ddH2Adding O +30 mu LFapon DNAclear Beads into 55 mu L of the reaction product in the previous step, uniformly mixing by vortex, collecting the liquid on the tube wall instantly, and standing for 5min at room temperature;
place 1.5mL tube or octal tube on magnetic rack until the solution in the tube is clear.
Carefully pipette the supernatant into a new 1.5mL EP tube or an octal tube (note: do not discard the supernatant), add 15. mu.L of Fapon DNA clean Beads, mix well, and stand at room temperature for 5 min;
note that: the supernatant is reserved in the operation, and the magnetic beads on the tube wall are not required to be contacted in the transferring process;
placing the EP tube or the eight-connected tube on a magnetic frame, and removing supernatant after the solution in the tube is clarified;
note that: this step should retain the beads.
Adding 200 mu L of freshly prepared 80% ethanol into an EP tube or an eight-connection tube, rotating a 1.5mL tube for one circle, standing the eight-connection tube for 30s, and then removing a supernatant;
repeating the steps, and removing the supernatant as much as possible;
placing a 1.5mL tube or an eight-connection tube on a magnetic frame, standing at room temperature for 10min until the magnetic beads are dried or opening the tube and placing the tube on a 45 ℃ metal bath until the surfaces of the magnetic beads are free of water;
removing the centrifugal tube from the magnetic frame, adding 22 mu L of ddH2O for resuspension of magnetic beads, uniformly mixing by vortex or blowing, collecting the liquid on the tube wall instantly, and standing at room temperature for 2 min;
the EP tube or the octal tube is placed on a magnetic rack, and after the solution in the tube is clarified, 20. mu.L of the supernatant is transferred to a new PCR tube for the next amplification.
Library amplification (library amplification):
preparing a library amplification reaction system on an ice box:
setting up a library amplification reaction program:
the cycle numbers are referenced as follows:
Total DNA input | Recommended PCR cycles | Total DNA input | Recommended PCR cycles |
1ug | 5 | 50ng | 10-11 |
500ng | 6-8 | 10ng | 12-13 |
100ng | 8-9 | 5ng | 13-15 |
and (3) purifying an amplification product:
vortex Fapon DNA clean Beads, resuspend them;
transferring the PCR product to a new 1.5mL tube or an eight-linked tube, adding 0.8X (40. mu.L) Fapon DNA clean Beads, mixing uniformly by vortex, collecting the tube wall liquid instantly, and standing at room temperature for 5 min;
placing 1.5mL tube or eight-connected tube on a magnetic frame, standing for 2min, and standing until the solution in the tube is clear;
carefully sucking and discarding supernatant liquid, adding 200 μ L of newly prepared 80% ethanol into the tube, rotating the tube on a magnetic frame, and discarding supernatant after the solution is clarified;
repeating the steps, and removing the supernatant as much as possible;
and (3) placing a 1.5mL tube or an eight-connected tube on a magnetic frame, standing at room temperature for 10min until the magnetic beads are dried or opening the tube and placing the tube on a 45 ℃ metal bath until the surfaces of the magnetic beads have no water.
Adding 28 μ L ddH2O into the EP tube or the eight-link tube, blowing, beating, mixing, standing for 2min, and placing the EP tube on a magnetic frame until the liquid becomes clear;
and sucking 25 mu L of supernatant into a new 1.5mL EP tube, adhering a library label on the tube wall, using Qsep400 to check the quality to be qualified, and storing the product in a special library storage position at the temperature of-20 ℃.
Pre-quality inspection (Qsep400) and sequencing results on the resulting library
FIG. 1 and FIG. 2 show the pre-machine Qsep400 quality inspection of the library, and the number LR201015-0100(A1) is a kit for extracting the competitive products(magenta, D3141) and kit for building a database from a competitive product: (UltraTMII, DNA Library Prep Kit, E7645S) Library quality inspection results, and LR201015-0101(B1) is a quality inspection result of a Library part built by a competitive product extraction Kit (magenta, D3141) + a self-research Kit; no. LR201015-0102(C1) self-research kit extraction part and competitive product library-building kit (C201015-0102)UltraTMII, DNA Library Prep Kit, E7645S) Library quality inspection results, and LR201015-0103(D1) is Library quality inspection results of an extraction part and a Library building part of the self-research Kit; LR201015-0104(E1) is a competitive extraction kit (assist in, 18820ES50) and a competitive library kit (E201015-E8932) ((R))UltraTMII DNA Library Prep Kit, E7645S), LR201015-0105(F1), Library-building partial quality test results for competitive extraction Kit (assist in san-out, 18820ES50) and self-research Kit. FIG. 3 shows the results of the sequencing data confirmatory analysis, and the self-research kit is not significantly different from the competitive kit.
Claims (7)
1. A nucleic acid extraction kit for use in the construction of a genomic library of pathogenic microorganisms in human feces, comprising: a nucleic acid releasing agent LysisA, an Enhancer Lysis Enhancer, a de-inhibitor IRT, a Binding solution Binding Buffer, a washing solution 1 and a washing solution 2;
the nucleic acid releasing agent lysine A comprises 20 mM-40 mM EDTA, 40 mM-80 mM Tris-HCl, 2% -5% PVP-40 (mass fraction), a solvent DEPC water and a pH value of 9-10;
the Enhancer lysine Enhancer comprises 12-15% of SDS (mass fraction), 4-8% of PVP-40 (mass fraction) and DEPC water as a solvent.
2. The nucleic acid kit according to claim 1, wherein the nucleic acid releasing agent lysine A comprises 20mM EDTA, 50mM Tri-HCl, 2% PVP-40 (mass fraction), and DEPC water as a solvent, and the Enhancer lysine Enhancer comprises 15% SDS (mass fraction), 5% PVP-40 (mass fraction), and DEPC water as a solvent.
3. The nucleic acid kit of claim 1, wherein the de-inhibitor IRT comprises: 120mM NH4Al(SO4)2.12H2O, DEPC water is used as a solvent, and the pH value is 3.0-4.0;
the Binding solution Binding Buffer comprises: 3M guanidinium isothiocyanate, 16.7% isopropanol (V/V), 2% Triton X100(V/V), 10mM EDTA, 5mM Tris-HCl in DEPC water at pH 6.0-7.0;
the washing solution 1 comprises: 20% ethanol (V/V), 20% isopropanol (V/V), 70mM sodium chloride, 20mM Tris-HCl, DEPC water as solvent, and pH 6.0-7.0;
the washing liquid 2 comprises: 70% ethanol (V/V), 20mM Tris-HCl, DEPC water as solvent, pH 6.0-7.0.
4. A kit for the fragmentation treatment and end modification of a pathogenic microorganism genome library in human feces is characterized by comprising AC buffers and AC Enzymes;
the AC Buffer comprises: 500mM Tris-HCl, 200mM KCl, 100mM MgCl2, 1mM DTT, 10mM MATP, 10mM dATP, 2mM dTTP, 2mM dGTP, 2mM dCTP, 0.1% Triton X-100(v/v), and the solvent is DEPC water;
the AC Enzymes comprise: 1.5U/ul T4 Polynucleotide Kinase (Enzymatics, Y9040L), 1U/ul T4 DNApolymerase (Enzymatics, P7080L), 0.5U/ul Klenow Fragment (Enzymatics, P7060L), 1U/ul Taq-B DNApolymerase (Enzymatics, P7250L), 4mM Tris-HCl, 5mM KCl, 0.8mM DTT, 0.2mM EDTA, 22% (mass fraction) Glycerol, 0.5% Triton X-100(v/v), and DEPC water as a solvent.
5. A kit for connecting and enriching joints of a pathogenic microorganism genome library in human excrement is characterized by comprising Ligation XP and AD Buffer;
the Ligation XP comprises: 14% Glycerol (v/v), 20% PEG-6000 (mass fraction), 25% 1,2-Propanediol (v/v), 40mM Tris-HCl, 10mM MgCl2, 10mM MATP, 10mM DTT, 80U/ul Rapid 4 DNAIGAse (EnzyValley), and DEPC water as a solvent;
the AD Buffer comprises: 10mM Tris-HCl, 0.5mM EDTA, 50mM NaCl, and DEPC water as solvent.
6. A nucleic acid extraction method for a pathogenic microorganism genome library in human excrement is characterized by comprising the following steps:
nucleic acid release: transferring the excrement sample to a bead grinding tube for grinding beads, adding a nucleic acid releasing agent LysisA and an Enhancer Lysis Enhancer into the sample, performing vortex scattering on the sample, incubating, and putting the grinding tube into a bead grinding instrument for bead grinding;
inhibitor removal: transferring all the supernatant into a centrifuge tube, adding inhibitor-removed IRT into the supernatant, uniformly mixing by vortex, and centrifuging;
column adsorption, namely transferring the supernatant into a centrifuge tube, adding Binding solution Binding Buffer into the supernatant, reversing and uniformly mixing to obtain mixed solution, putting a purification column into a collection tube, transferring the mixed solution into a column, centrifuging to discard effluent, and putting the column back into the collection tube;
desalting: adding washing solution 1 into the column, centrifuging, pouring off the filtrate, putting the column back into the collecting pipe, adding washing solution 2 into the column, centrifuging, repeating the operation of washing solution 2 for several times, pouring off the filtrate, putting the column back into the collecting pipe, and centrifuging;
nucleic acid elution: the column was placed in a centrifuge tube, sterilized water was added to the center of the membrane of the column, and the column was left at room temperature and then centrifuged to obtain nucleic acid.
7. A method for building a database of pathogenic microorganism genomes in human excrement is characterized by comprising the following steps:
dna fragmentation:
preparing a breaking system in 50ul breaking pipes, and selecting corresponding breaking time according to different breaking systems:
B. end repair (A-Tailed Conversion):
preparing a terminal repair reaction system in a 0.2mL PCR tube:
blowing and beating for at least 10 times or carrying out vortex oscillation and uniform mixing, and carrying out short-time centrifugation to collect liquid on the pipe/hole wall;
the reaction system was placed on a PCR instrument with the hot lid set at 80 ℃ and the following procedure was run:
·20℃30min;
·65℃30min;
·4℃Forever
C. connecting joints:
5min before the ligation reaction, the Adapter working solution was prepared according to the following table and placed on ice for use:
the following reagents were added directly to the end-repair reaction system:
placing the reaction system on a PCR instrument, setting the temperature of a hot cover as Off, and incubating for 20min at 20 ℃;
D. fragment selection and purification
Taking the Fapon DNA clean Beads out, standing to room temperature, and uniformly mixing in a vortex manner for later use;
to a 1.5mL tube or octal tube was added 30. mu.L ddH2Adding O +30 mu LFapon DNA clean Beads into 55 mu L of the reaction product in the previous step, uniformly mixing by vortex, collecting the liquid on the tube wall instantly, and standing for 5min at room temperature;
placing a 1.5mL tube or an eight-connected tube on a magnetic frame until the solution in the tube is clarified;
carefully sucking the supernatant into a new 1.5mL EP tube or an eight-linked tube, adding 15 μ L Fapon DNA clean Beads, mixing well, and standing at room temperature for 5 min;
placing the EP tube or the eight-connected tube on a magnetic frame, and removing supernatant after the solution in the tube is clarified;
adding 200 mu L of freshly prepared 80% ethanol into an EP tube or an eight-connection tube, rotating a 1.5mL tube for one circle, standing the eight-connection tube for 30s, and then removing a supernatant;
repeating the steps, and removing the supernatant as much as possible;
placing a 1.5mL tube or an eight-connection tube on a magnetic frame, standing at room temperature for 10min until the magnetic beads are dried or opening the tube and placing the tube on a 45 ℃ metal bath until the surfaces of the magnetic beads are free of water;
removing the centrifugal tube from the magnetic frame, adding 22 mu L of ddH2O for resuspension of magnetic beads, uniformly mixing by vortex or blowing, collecting the liquid on the tube wall instantly, and standing at room temperature for 2 min;
placing the EP tube or the eight-connected tube on a magnetic frame, transferring 20 mu L of supernatant into a new PCR tube after the solution in the tube is clarified, and carrying out the next amplification;
C. library amplification:
preparing a library amplification reaction system on an ice box:
setting up a library amplification reaction program:
the cycle numbers are referenced as follows:
D. and (3) purifying an amplification product:
vortex Fapon DNA clean Beads, resuspend them;
transferring the PCR product to a new 1.5mL tube or an eight-connected tube, adding 0.8X 40 mu L Fapon DNA clean Beads, mixing uniformly by vortex, collecting the tube wall liquid instantly, and standing at room temperature for 5 min;
placing 1.5mL tube or eight-connected tube on a magnetic frame, standing for 2min, and standing until the solution in the tube is clear;
carefully sucking and discarding supernatant liquid, adding 200 μ L of newly prepared 80% ethanol into the tube, rotating the tube on a magnetic frame, and discarding supernatant after the solution is clarified;
repeating the steps, and removing the supernatant as much as possible;
placing a 1.5mL tube or an eight-connection tube on a magnetic frame, standing at room temperature for 10min until the magnetic beads are dried or opening the tube and placing the tube on a 45 ℃ metal bath until the surfaces of the magnetic beads are free of water;
adding 28 μ L ddH2O into the EP tube or the eight-link tube, blowing, beating, mixing, standing for 2min, and placing the EP tube on a magnetic frame until the liquid becomes clear;
and sucking 25 mu L of supernatant into a new 1.5mL EP tube, adhering a library label on the tube wall, using Qsep400 to check the quality to be qualified, and storing the product in a special library storage position at the temperature of-20 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110275849.XA CN113046414A (en) | 2021-03-15 | 2021-03-15 | Kit for human fecal pathogenic microorganism genome library construction and sequencing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110275849.XA CN113046414A (en) | 2021-03-15 | 2021-03-15 | Kit for human fecal pathogenic microorganism genome library construction and sequencing method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113046414A true CN113046414A (en) | 2021-06-29 |
Family
ID=76512301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110275849.XA Pending CN113046414A (en) | 2021-03-15 | 2021-03-15 | Kit for human fecal pathogenic microorganism genome library construction and sequencing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113046414A (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1677106A (en) * | 2005-02-02 | 2005-10-05 | 东北农业大学 | Technology for treating excrement and urine in pig's infectious gastroenteritis quick testing method |
CN101307311A (en) * | 2008-07-14 | 2008-11-19 | 四川大学 | Process for abstracting total DNA of swine waste sample |
CN101613696A (en) * | 2009-08-05 | 2009-12-30 | 公安部物证鉴定中心 | Extract the reagent of purify DNA |
CN101712953A (en) * | 2009-12-24 | 2010-05-26 | 上海市农业科学院 | DNA extracting method for evaluating community diversity of the intestinal microorganisms of animals |
CN102864138A (en) * | 2012-09-03 | 2013-01-09 | 浙江世纪康大医疗科技有限公司 | Human feces DNA extraction method |
CN102978198A (en) * | 2012-11-29 | 2013-03-20 | 上海市农业科学院 | Microbial genome DNA (deoxyribonucleic acid) indirect extraction method for evaluating diversity of animal intestinal microflora |
CN108368539A (en) * | 2015-09-10 | 2018-08-03 | 生命技术公司 | Nucleic acid purification in environment or biological sample |
CN109266642A (en) * | 2017-07-18 | 2019-01-25 | 天根生化科技(北京)有限公司 | The kit and extracting method of paramagnetic particle method extraction fecal microorganism genome |
CN110904098A (en) * | 2019-12-31 | 2020-03-24 | 杭州海基生物技术有限公司 | Lysis binding solution and nucleic acid extraction by feces magnetic bead method |
CN112004927A (en) * | 2018-04-27 | 2020-11-27 | 恰根有限公司 | Method for isolating nucleic acids from plant samples |
-
2021
- 2021-03-15 CN CN202110275849.XA patent/CN113046414A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1677106A (en) * | 2005-02-02 | 2005-10-05 | 东北农业大学 | Technology for treating excrement and urine in pig's infectious gastroenteritis quick testing method |
CN101307311A (en) * | 2008-07-14 | 2008-11-19 | 四川大学 | Process for abstracting total DNA of swine waste sample |
CN101613696A (en) * | 2009-08-05 | 2009-12-30 | 公安部物证鉴定中心 | Extract the reagent of purify DNA |
CN101712953A (en) * | 2009-12-24 | 2010-05-26 | 上海市农业科学院 | DNA extracting method for evaluating community diversity of the intestinal microorganisms of animals |
CN102864138A (en) * | 2012-09-03 | 2013-01-09 | 浙江世纪康大医疗科技有限公司 | Human feces DNA extraction method |
CN102978198A (en) * | 2012-11-29 | 2013-03-20 | 上海市农业科学院 | Microbial genome DNA (deoxyribonucleic acid) indirect extraction method for evaluating diversity of animal intestinal microflora |
CN108368539A (en) * | 2015-09-10 | 2018-08-03 | 生命技术公司 | Nucleic acid purification in environment or biological sample |
CN109266642A (en) * | 2017-07-18 | 2019-01-25 | 天根生化科技(北京)有限公司 | The kit and extracting method of paramagnetic particle method extraction fecal microorganism genome |
CN112004927A (en) * | 2018-04-27 | 2020-11-27 | 恰根有限公司 | Method for isolating nucleic acids from plant samples |
CN110904098A (en) * | 2019-12-31 | 2020-03-24 | 杭州海基生物技术有限公司 | Lysis binding solution and nucleic acid extraction by feces magnetic bead method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111118226B (en) | Novel coronavirus whole genome capture method, primer group and kit | |
CN111188094A (en) | Sequencing library construction method and kit for pathogenic microorganism detection | |
CN111471676A (en) | Preparation method of database building sample for metagenome next generation sequencing | |
JP6559647B2 (en) | One-step nucleic acid amplification method for non-eluting samples | |
CN110886021B (en) | Construction method of single-cell DNA library | |
WO2017193833A1 (en) | Method and kit comprising 4,000 human pathogenic target genes | |
CN112011835A (en) | Construction method of sequencing library for pathogenic microorganism detection | |
CN113249439A (en) | Construction method of simplified DNA methylation library and transcriptome co-sequencing library | |
CN110343754A (en) | A method of it is quickly detected for hematopoietic stem cell transplantation donor pathogenic microorganism | |
CN111748628B (en) | Primer and kit for detecting thyroid cancer prognosis related gene variation | |
CN107858409A (en) | A kind of micro degrading genes group DNA methylation builds storehouse sequence measurement and its kit | |
WO2021253372A1 (en) | High-compatibility pcr-free library building and sequencing method | |
CN111662959A (en) | High-throughput rapid detection method for fungi | |
CN116515952A (en) | Reagent and method for rapidly detecting methylation of urinary shed cell genes | |
WO2021027236A1 (en) | Method for constructing dna library and application thereof | |
CN113322523B (en) | RNA rapid library construction method and application thereof | |
JP2022145606A (en) | Highly sensitive methods for accurate parallel quantification of nucleic acids | |
CN113564227A (en) | Method for rapidly separating DNA (deoxyribonucleic acid) of host and pathogenic microorganism based on CRISPR/dcas9 | |
US20180002731A1 (en) | Methods of constructing a circular template and detecting dna molecules | |
CN116904568A (en) | Method for removing ribosomal RNA in RNA-seq | |
CN113046414A (en) | Kit for human fecal pathogenic microorganism genome library construction and sequencing method | |
CN114351261A (en) | Method for detecting respiratory tract sample difficultly-detected pathogenic microorganisms based on nanopore sequencing platform | |
CN113980960A (en) | Specific primer and method for searching combination of known promoter sequence and unknown protein | |
JP2022533269A (en) | Method for detecting rare DNA sequences in stool samples | |
CN118086284A (en) | Method for separating and enriching annular mitochondrial genome in human whole blood sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |